Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 22 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

45%

10 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

10(45.5%)

Phase 1

8(36.4%)

Phase 2

3(13.6%)

N/A

1(4.5%)

22Total

Phase 3(10)

Phase 1(8)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT06838195Phase 3Active Not Recruiting

Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine

Role: lead

NCT06703203Phase 1Completed

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

Role: lead

NCT06970756Phase 1Not Yet Recruiting

A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60

Role: lead

NCT06817187Phase 3Completed

Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine

Role: lead

NCT06350058Phase 1Active Not Recruiting

Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old

Role: lead

NCT05252715Phase 3Active Not Recruiting

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Role: lead

NCT06314867Phase 3Active Not Recruiting

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

Role: lead

NCT06314880Phase 1Recruiting

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Role: lead

NCT06314685Phase 3Active Not Recruiting

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Role: lead

NCT06314659Phase 3Active Not Recruiting

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

Role: lead

NCT06344065Phase 3Recruiting

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

Role: lead

NCT05939219Not ApplicableUnknown

Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine

Role: lead

NCT05913024Phase 2Completed

Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months

Role: lead

NCT05229536Phase 2Completed

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Role: lead

NCT04865497Phase 2Completed

Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old

Role: lead

NCT05156528Phase 3Unknown

Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years

Role: lead

NCT04357522Phase 3Not Yet Recruiting

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

Role: lead

NCT04278248Phase 3Completed

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

Role: lead

NCT04108845Phase 1Unknown

Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months

Role: lead

NCT03561181Phase 1Completed

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Role: lead